The increased frequency of heterozygotes for a,-AT phenotypes among mothers of children with chromosomal aberrations noted by Aarskog and Fagerholl suggested a relationship between a,-AT phenotypes and chromosomal abnormalities. This observation has been extended by Kueppers et a12 who noted an excess of heterozygotes in the combined parental group as well as among patients with chromosomal abnormalities. Similarly, Fineman et al3 noted an increased frequency of heterozygotes among Down's syndrome patients in the older mothers groups; distribution of al-AT phenotypes among parents were not determined. However, Arnaud et a14 were unable to observe any significant differences in the distribution of ao-AT phenotypes between Down's syndrome patients and controls.
In view of these contradictions, we report the results of investigations on oxl-antitrypsin phenotypes as well as quantification of o2-macroglobulin in Down's syndrome, non-specific mental retardation, and in controls for an Australian population. total heterozygosity (11 -5 % among Down's syndrome, 10-9 % among non-specific mental retardation patients, and 11 % among newborn infants). Evans et allt reported differences in the relative concentrations of proteins in the electrophoretic bands 4 and 6, numbering being in order of decreasing anodal mobility. Among newborn children, the relative anodal bands, notably band 4, are more intense, the pattern being reversed after birth. The control population consisted of newborn children and a similar pattern was observed, even though isoelectric focusing rather than starch gel electrophoresis was used. These changes may represent developmental changes in the relative activities of multiple molecular forms of a,-antitrypsin. The significance of these changes is yet to be elucidated. o2-macroglobulin, one of the antiproteases found in comparable concentrations in human serum, is capable of inhibiting trypsin in common with x,-AT. 
